Denali Therapeutics Inc (DNLI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.00B
Last updated: Nov 17, 2026 at 11:04 AM ET
Denali Therapeutics Inc (DNLI) Earnings: Report Dates and Results
Denali Therapeutics (DNLI) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Denali Therapeutics reported EPS of -$0.64, above the -$0.69 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
DNLI has an expected report date of Feb 24, 2027.
DNLI Earnings Call
The latest DNLI earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 36 quarters below that had an estimate, DNLI beat 19, missed 16 and matched 1. The widest gap in the table came in the quarter ended Dec 31, 2018, when EPS landed 818.18% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.64 | -$0.69 | -$0.88 - $0.38 | +7.25% | Beat | N/A | 17 | N/A | Nov 3, 2026 | $17.78M |
| Jun 30, 2026 | -$0.68 | -$0.72 | -$0.89 - $0.36 | +5.56% | Beat | N/A | 15 | 1 up, 0 down | Aug 6, 2026 | $3.60M |
| Mar 31, 2026 | -$0.69 | -$0.71 | -$0.80 - -$0.54 | +2.82% | Beat | N/A | 12 | 4 up, 1 down | May 7, 2026 | N/A |
| Dec 31, 2025 | -$0.73 | -$0.75 | -$0.93 - -$0.62 | +2.67% | Beat | N/A | 15 | 1 up, 0 down | Feb 26, 2026 | N/A |
| Sep 30, 2025 | -$0.74 | -$0.76 | -$0.88 - -$0.68 | +2.63% | Beat | N/A | 15 | 6 up, 2 down | Nov 6, 2025 | N/A |
| Jun 30, 2025 | -$0.72 | -$0.74 | -$0.93 - -$0.43 | +2.70% | Beat | N/A | 14 | 1 up, 0 down | Aug 11, 2025 | N/A |
| Mar 31, 2025 | -$0.78 | -$0.70 | -$0.77 - -$0.57 | -11.43% | Miss | N/A | 12 | 2 up, 1 down | May 6, 2025 | N/A |
| Dec 31, 2024 | -$0.67 | -$0.85 | -$1.13 - -$0.41 | +20.79% | Beat | N/A | 12 | 1 up, 2 down | Feb 27, 2025 | N/A |
| Sep 30, 2024 | -$0.63 | -$0.63 | -$0.74 - -$0.45 | 0.00% | In line | N/A | 16 | 1 up, 0 down | Nov 6, 2024 | N/A |
| Jun 30, 2024 | -$0.59 | -$0.69 | -$0.85 - -$0.43 | +14.49% | Beat | -145.4% | 16 | 1 up, 0 down | Aug 1, 2024 | N/A |
| Mar 31, 2024 | -$0.78 | -$0.66 | -$0.86 - -$0.53 | -18.18% | Miss | N/A | 15 | 2 up, 0 down | May 7, 2024 | N/A |
| Dec 31, 2023 | -$0.86 | -$0.80 | -$0.96 - -$0.71 | -7.50% | Miss | N/A | 15 | 0 up, 0 down | Feb 27, 2024 | N/A |
| Sep 30, 2023 | -$0.72 | -$0.79 | -$1.00 - -$0.65 | +8.86% | Beat | N/A | 13 | 0 up, 0 down | Nov 7, 2023 | $1.27M |
| Jun 30, 2023 | $1.30 | -$0.63 | -$0.99 - $1.03 | +306.35% | Beat | N/A | 12 | 0 up, 0 down | Aug 8, 2023 | $294.12M |
| Mar 31, 2023 | -$0.80 | -$0.70 | -$0.84 - -$0.54 | -14.29% | Miss | N/A | 12 | 0 up, 0 down | May 8, 2023 | $35.14M |
| Dec 31, 2022 | -$0.75 | -$0.79 | -$0.98 - -$0.41 | +5.06% | Beat | N/A | 15 | 0 up, 0 down | Feb 27, 2023 | $10.28M |
| Sep 30, 2022 | -$0.84 | -$0.79 | -$0.90 - -$0.48 | -6.33% | Miss | N/A | 11 | 1 up, 0 down | Nov 3, 2022 | $3.56M |
| Jun 30, 2022 | -$0.48 | -$0.55 | -$0.81 - -$0.34 | +12.73% | Beat | N/A | 11 | 1 up, 0 down | Aug 8, 2022 | $52.48M |
| Mar 31, 2022 | -$0.53 | -$0.45 | -$0.73 - $0.04 | -17.78% | Miss | N/A | 11 | 0 up, 1 down | May 5, 2022 | $42.14M |
| Dec 31, 2021 | -$0.62 | -$0.41 | -$0.72 - $0.39 | -51.22% | Miss | -132.5% | 13 | 0 up, 0 down | Feb 28, 2022 | $12.51M |
| Sep 30, 2021 | -$0.69 | -$0.38 | -$0.66 - -$0.10 | -81.58% | Miss | N/A | 13 | N/A | Nov 4, 2021 | $5.29M |
| Jun 30, 2021 | -$0.50 | -$0.36 | -$0.62 - -$0.10 | -38.89% | Miss | N/A | 10 | N/A | Aug 4, 2021 | $22.94M |
| Mar 31, 2021 | -$0.58 | -$0.34 | -$0.69 - -$0.02 | -70.59% | Miss | N/A | 9 | N/A | May 3, 2021 | $7.92M |
| Dec 31, 2020 | $1.91 | -$0.60 | -$0.67 - $2.57 | +418.33% | Beat | N/A | 9 | N/A | Feb 25, 2021 | $316.81M |
| Sep 30, 2020 | -$0.54 | $2.20 | -$0.61 - $4.65 | -124.55% | Miss | N/A | 8 | N/A | Nov 5, 2020 | $9.39M |
| Jun 30, 2020 | -$0.56 | -$0.61 | -$0.65 - -$0.54 | +8.20% | Beat | N/A | 10 | N/A | Aug 7, 2020 | $5.85M |
| Mar 31, 2020 | -$0.55 | -$0.57 | -$0.65 - -$0.49 | +3.51% | Beat | N/A | 12 | N/A | May 7, 2020 | $3.60M |
| Dec 31, 2019 | -$0.56 | -$0.58 | -$0.69 - -$0.14 | +3.45% | Beat | -170.9% | 11 | N/A | Feb 27, 2020 | $4.67M |
| Sep 30, 2019 | -$0.48 | -$0.55 | -$0.71 - -$0.39 | +12.73% | Beat | N/A | 10 | N/A | Nov 6, 2019 | $13.60M |
| Jun 30, 2019 | -$0.61 | -$0.46 | -$0.50 - -$0.41 | -32.61% | Miss | N/A | 7 | N/A | Aug 6, 2019 | $4.20M |
| Mar 31, 2019 | -$0.41 | -$0.44 | -$0.48 - -$0.18 | +6.82% | Beat | N/A | 6 | N/A | May 8, 2019 | $4.21M |
| Dec 31, 2018 | $0.79 | -$0.11 | -$0.46 - $0.94 | +818.18% | Beat | N/A | 6 | N/A | Mar 12, 2019 | $125.68M |
| Sep 30, 2018 | -$0.38 | -$0.29 | N/A | -31.03% | Miss | N/A | N/A | N/A | Nov 8, 2018 | $1.20M |
| Jun 30, 2018 | -$0.59 | -$0.22 | -$0.23 - -$0.16 | -168.18% | Miss | N/A | 3 | N/A | Aug 9, 2018 | $1.65M |
| Mar 31, 2018 | -$0.26 | $0.30 | N/A | -186.67% | Miss | N/A | 2 | N/A | May 11, 2018 | $641000 |
| Dec 31, 2017 | -$0.74 | -$0.20 | -$0.30 - $0.00 | -270.00% | Miss | N/A | 3 | N/A | Mar 19, 2018 | $145.15M |
| Sep 30, 2017 | -$0.53 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 8, 2017 | N/A |
| Mar 31, 2017 | -$2.36 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 4, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.97, after -$2.67 the year before. It was -$3.63 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.97 | N/A |
| Dec 31, 2024 | -$2.67 | N/A |
| Dec 31, 2023 | -$1.08 | N/A |
| Dec 31, 2022 | -$2.60 | N/A |
| Dec 31, 2021 | -$2.39 | -1019.2% |
| Dec 31, 2020 | $0.26 | N/A |
| Dec 31, 2019 | -$2.06 | N/A |
| Dec 31, 2018 | -$0.44 | N/A |
| Dec 31, 2017 | -$3.63 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,600 words across 23 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,645 | 23 | |
| 2026Q2 | Jun 30, 2026 | 8,892 | 22 |
2026Q3 Earnings Call
Opening remarks
Laura Hansen VP, Investor Relations Good afternoon, everyone, and thank you for joining us to discuss Denali Therapeutics Third Quarter 2026 Financial Results and Business Highlights. Earlier today, we issued our press release and filed our quarterly report. The press release and today's presentation are available in the Investor Relations section of our website. Before we begin, on Slide 2, I'd like to remind everyone that today's discussion includes forward-looking statements, including our expectations for fourth quarter AVLAYAH net product revenue and the timing and availability of clinical data and any regulatory submissions. These statements reflect our current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings and to the cautionary language in today's release and presentation. Denali undertakes no obligation to update these statements, except as required by law. Joining me today are Ryan Watts, our Chief Executive Officer; Katie Peng, our Chief Commercial Officer; Peter Chin, our Chief Medical Officer and Head of Development; and Alexander Schuth, our Chief Operating and Financial Officer. Ryan will open with our progress this quarter. Katie will cover the AVLAYAH launch. Peter will review the clinical programs, and Alex will discuss our financial results before Ryan opens the Q&A session. Ryan?
Ryan Watts CEO Slide 4. Thanks, Laura, and thank you all for joining us today. This was a defining quarter for Denali, and we are excited to share it with you. I want to start where we always do with our purpose: transforming life for people living with serious disease. We are focused on making a real difference for children, adults and families by delivering medicines across the blood-brain barrier and into the brain. In recent weeks, we have spent time with Hunter syndrome families, hearing directly what this disease asks of their children and what families hope AVLAYAH can offer. This brings our purpose into focus. Their trust is a responsibility we carry into the launch and into every program we advance. Slide 5. It starts with AVLAYAH, but it is bigger than one medicine. For the Hunter syndrome community, AVLAYAH is the first new FDA-approved therapy in nearly 20 years. It is the first FDA-approved medicine of its kind designed to cross the blood-brain barrier through the transferrin receptor and the first to come from our TransportVehicle platform. That is a milestone for patients and a milestone for our field. AVLAYAH gives Denali something we have worked toward for a long time: a commercial product that shows what our TransportVehicle platform can do. That same delivery capability underpins a broad pipeline across rare and common diseases. Our ambition now is to repeat what we have achieved in Hunter syndrome, program after program. Slide 6.
Frequently Asked Questions About DNLI
When is Denali Therapeutics's next earnings date?
Denali Therapeutics's next earnings report is expected for Feb 24, 2027.
Did DNLI beat earnings estimates last quarter?
Yes. Denali Therapeutics reported EPS of -$0.64 for the quarter ended Sep 30, 2026, above the -$0.69 estimate, a 7.25% surprise.
What EPS do analysts expect from DNLI next quarter?
The consensus EPS estimate for Denali Therapeutics for the quarter ending Dec 31, 2026 is -$0.63 from 22 analysts, with estimates from -$0.74 to -$0.48.
How often does DNLI beat earnings estimates?
Denali Therapeutics beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +4.12%.
DNLI pages: Overview, Earnings, Forecast, Financials, Competitors